Design Therapeutics, Inc. (DSGN) analyst actions
Rating and price-target actions on DSGN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the DSGN overview →
1 measured DSGN analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1 | Press release | -2.46% | +1.54% |
Keep exploring
More DSGN: earnings → · SEC filings → · DSGN overview →